

3rd Quarter 2026 Earnings Release Presentation

October 29, 2026

Cautionary Statements

This presentation includes “forward-looking statements.” These statements relate to future events, including, but not limited to, statements regarding our liquidity, operating results, future earnings, financial position, operational and strategic initiatives, and developments in legislation, regulation, and the healthcare industry more generally. These forward-looking statements represent management’s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are uncertain. Actual results, performance or achievements could differ materially from those expressed in any forward-looking statement.

Examples of uncertainties that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements include, but are not limited to, the factors described under “Forward-Looking Statements” and “Risk Factors” in our Forms 10-Q, 10-K, and other filings with the Securities and Exchange Commission. We assume no obligation to update any forward-looking statements or information subsequent to the dates such statements are made. Investors are cautioned not to place undue reliance on our forward-looking statements.

NON-GAAP FINANCIAL INFORMATION

This presentation contains financial measures that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of these non-GAAP measures to the most comparable GAAP measures and management’s reasoning for using these non-GAAP financial measures are included in our earnings press releases dated February 11, 2026 and October 29, 2026, which are available on our website at www.tenethealth.com/investors. We are not able to reconcile certain forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures without unreasonable efforts due to uncertainty regarding items outside of our control.

Third Quarter 2026 Highlights*

Consolidated Adjusted EBITDA of $1.355 billion, exceeding our expectations, driven by sustained fundamental performance. Also includes $147 million of favorable net impact from transition activities.

79.5% Adjusted Diluted EPS Growth

23.3% Adjusted EBITDA Growth

24.1% Consolidated Adjusted EBITDA Margin

Ambulatory

- 9.1% Adjusted EBITDA growth; represents 24.5% of FY26 EBITDA guidance
- 4.5% same-facility revenue growth
- 39.2% Adjusted EBITDA margin
- 6 facilities added in third quarter

Hospitals

- 3.2% Adjusted admissions growth over Q3'25
- 34.8% Adjusted EBITDA growth over Q3'25
- 19.2% Adjusted EBITDA margin
- Consolidated SW&B as a % of revenue: 38.6% Q3'26, 41.7% Q3'25

FY 2026 Adjusted Outlook increased $195 million – Now Expect Consolidated Adjusted EBITDA of $5.050 to $5.200 billion**

Now Expect FY 2026 Adjusted Free Cash Flow – NCI Outlook of $1.925 to $2.155 billion***, a $100 million increase**

- * Metrics on this slide include $147M of favorable net impact from transition activities
- ** 2026 Financial Outlook is based on the Company's Outlook as of October 29, 2026
- *** Includes $150M income tax payment associated with the RCM contract termination

2026 Financial Outlook*

Net operating revenues	$22.05 to $22.45B
Adjusted EBITDA	
Ambulatory	$2.16 to $2.22B
Hospitals	$2.89 to $2.98B
Consolidated	$5.05 to $5.20B
Adjusted EBITDA margin	22.9% to 23.2%

Continued strength in Adjusted EBITDA growth and Free Cash Flow - NCI

Changes vs. Prior Year

Ambulatory same-facility system-wide revenues	Up 3 - 6%
Inpatient admissions	Up 1 - 2%
Adjusted admissions	Up 1 - 2%

Capital Deployment

Adjusted Net Cash Provided by Operating Activities	$3.525 to $3.925B**
Capital expenditures	$700 to $800M
Adjusted Free Cash Flow	$2.825 to $3.125B**
NCI cash distributions	$900 to $970M
Adjusted Free Cash Flow less NCI Distributions	$1.925 to $2.155B**

*2026 Financial Outlook is based on the Company's Outlook as of October 29, 2026
**Includes $150M income tax payment associated with the RCM contract termination

FY 2026 Adjusted EBITDA* Outlook Bridge from 2025 *($ in millions)*

($ in millions)	Ambulatory	Hospital	Total
2025 Adjusted EBITDA	**$2,026**	**$2,540**	**$4,566**
Supplemental Medicaid Revenue favorable out-of-period adjustments	-	($148)	($148)
2025 Normalized Performance	**$2,026**	**$2,392**	**$4,418**
Non-recurring Conifer Deferred Revenue Recognition	-	$40	$40
Impact from expiration of enhanced premium tax credits	($30)	($220)	($250)
Additional Supplemental Medicaid Revenue ($124m related to prior year)	-	$172	$172
Conifer Transition Impact	-	$160	$160
Growth & Cost Efficiencies	$194	$391	$585
2026 Adjusted EBITDA Guidance Mid-Point	**$2,190**	**$2,935**	**$5,125**
2026 Anticipated Growth versus 2025 Normalized	**8.1%**	**22.7%**	**16.0%**
2026 Anticipated Growth & Cost Efficiencies versus 2025 Normalized	**9.6%**	**16.3%**	**13.2%**

Expect strong revenue growth and operational performance to drive attractive Adjusted EBITDA growth

*2026 Adjusted EBITDA Outlook is based on the Company's Outlook as of October 29, 2026.

Conifer RCM Agreement Transition

As described in our earnings release, the transition of revenue cycle management services under the RCM Agreements occurred during the third quarter of 2026 and will be substantially complete by October 30, 2026. This transaction has impacted our financial statements primarily in the following ways in the third quarter of 2026:

- We recognized cumulative catch-up adjustments that increased revenue from contract termination by $233 million and net operating revenues by $97 million. These are timing related adjustments, and as such, do not impact total or full year 2026 expectations for revenue from contract termination or net operating revenues associated with the RCM Agreements.

- In addition, we recognized a benefit of approximately $50 million in the three months ended September 30, 2026 due to various transition activities, including efficiencies from the revised timeline described above. This, combined with the $97 million timing-related adjustments to net operating revenue mentioned above, resulted in a favorable net impact to Adjusted EBITDA of $147 million in the third quarter of 2026.

We expect the fourth quarter of 2026 to be impacted by this transition in the following ways:

- We expect a reduction in revenue from contract termination of $233 million and net operating revenues of $97 million.


- We expect an incremental $110 million of benefits to Adjusted EBITDA due to various transition activities, including efficiencies from the revised timeline described above under the RCM Agreements.

For full year 2026, we now expect various contract transition activities to contribute approximately $450 million of Adjusted EBITDA, inclusive of the $40 million deferred revenue adjustment recorded in the first quarter. We do not expect these contributions to recur in 2027. These reflect our best estimate of our current expectations, and we will update based on the actual results from the fourth quarter during our year-end earnings call.


USPI

USPI Track Record of Mid-teens Growth and Strong Margins

Net Revenue ($M)




Adjusted EBITDA ($M)



Consistent Track Record of ~40% Adjusted EBITDA Margins

USPI Long Term Organic Growth Consistency

6.1% Same-facility System-wide Revenue CAGR from 2015-2026



Organic Growth Rates Driven by USPI Leadership in Strategy & Execution

Established Expertise in Starting New Service Lines

381

Service Line Additions
YTD 2026

Expansion of High Acuity Cases


12.8%

Same-facility ASC
Total Joints Growth
Q3 2026*

*Same-facility ASCs excludes acquired facilities or de novos opened after September 30, 2025

USPI Case Mix / Clinical Quality

2025 Case Mix



Commitment to Quality Drives Strong Patient Experience




96.7

2025 Overall Patient Experience Score

USPI Acquisitions and De Novos Deliver Significant Returns on Invested Capital

Total Number of Facilities

2017 – 2026



Achievement of Attractive Returns

8-10x
Initial Acquisition Multiple

5-7x
Exceeded
*Targeted Acquisition Effective Multiple**


<2.0x
Exceeded
Targeted De Novo Effective Multiple

Dedicated development team and strong partnership economic returns drive competitive deal advantages

* Targeted Acquisition Effective Multiple generally realized over a three-year period post-acquisition

Cash Flow and Capital

2026 Cash Flows Continue to Support Growth / Deleveraging




- Our cash flow and balance sheet position provide significant capital allocation flexibility:
  - ✓ Ample liquidity and access to capital markets to pursue our growth strategy while returning capital to shareholders
- Third quarter 2026 M&A activity:
  - ✓ Acquired 6 ambulatory centers
- Repurchased ~970,000 shares in third quarter 2026 for $255 million
  - ✓ Repurchased 8.0 million shares for $1.615 billion year to date
- Retired $1.5 billion senior secured notes due in 2027 and $500 million of senior notes due in 2028 using newly issued $2.0 billion senior notes due in 2034
  - ✓ No significant debt maturities until 2028


* Subject to periodic updates to overall borrowing base capacity (as of September 30, 2026)

Significant Deleveraging of the Balance Sheet

LEVERAGE RATIO (EBITDA)



LEVERAGE RATIO (EBITDA-NCI)



Substantial reduction in leverage following significant performance improvement and hospital sales

Capital Deployment Priorities

We prioritize the deployment of the free cash flow generated by our businesses to the following areas:

Investments in our ASC Platform	M&A and de novo investments – baseline intention is $250 million per year
Investments in our Hospital Business	Continued investment in technology, robotics, and targeted surgical hospital expansion focused on higher acuity services
Share Repurchase Program	$1.88 billion share repurchase authorization remaining
Maintain a Deleveraged Balance Sheet	Commitment to a deleveraged balance sheet through earnings growth and debt repayment

GAAP to Non-GAAP Reconciliations

NON-GAAP FINANCIAL INFORMATION

This presentation contains financial measures that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of these non-GAAP measures to the most comparable GAAP measures and management's reasoning for using these non-GAAP measures are included in our earnings press release dated October 29, 2026. GAAP to non-GAAP reconciliations for those measures used in this slide presentation are also included on the following slides.

Supplemental Non-GAAP Disclosures

Table #1 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted Net Income Available to Common Shareholders

(Unaudited)

(Dollars in millions, except per share amounts)	Three Months Ended September 30, 2026	Three Months Ended September 30, 2025	Nine Months Ended September 30, 2026	Nine Months Ended September 30, 2025
Net income available to Tenet Healthcare Corporation common shareholders	**$ 1,000**	**$ 342**	**$ 2,528**	**$ 1,036**
Less:				
Revenue from contract termination	646	—	1,472	—
Impairment and restructuring charges, and acquisition-related costs	(37)	(23)	(92)	(66)
Litigation and investigation benefit (costs)	(6)	11	(36)	(34)
Net gains on sales, consolidation and deconsolidation of facilities	9	20	43	4
Loss from early extinguishment of debt	(5)	—	(5)	—
Tax and noncontrolling interests impact of above items	(142)	6	(325)	21
Adjusted net income available to common shareholders	**$ 535**	**$ 328**	**$ 1,471**	**$ 1,111**
Diluted earnings per share	**$ 12.41**	**$ 3.86**	**$ 30.08**	**$ 11.28**
Less:				
Revenue from contract termination	8.01	—	17.51	—
Impairment and restructuring charges, and acquisition-related costs	(0.46)	(0.26)	(1.09)	(0.72)
Litigation and investigation benefit (costs)	(0.07)	0.12	(0.43)	(0.37)
Net gains on sales, consolidation and deconsolidation of facilities	0.11	0.23	0.51	0.04
Loss from early extinguishment of debt	(0.06)	—	(0.06)	—
Tax and noncontrolling interests impact of above items	(1.76)	0.07	(3.86)	0.23
Adjusted diluted earnings per share	**$ 6.64**	**$ 3.70**	**$ 17.50**	**$ 12.10**
Weighted average basic shares outstanding (in thousands)	**80,134**	**87,951**	**83,486**	**91,109**
Weighted average dilutive shares outstanding (in thousands)	**80,600**	**88,610**	**84,053**	**91,805**

Supplemental Non-GAAP Disclosures

Table #2 – Reconciliations of Net Income Available to Tenet Healthcare Corporation Common Shareholders to Adjusted EBITDA

(Unaudited)

(Dollars in millions)	Three Months Ended September 30, 2026	Three Months Ended September 30, 2025	Nine Months Ended September 30, 2026	Nine Months Ended September 30, 2025
Net income available to Tenet Healthcare Corporation common shareholders	**$ 1,000**	**$ 342**	**$ 2,528**	**$ 1,036**
Less:				
Net income available to noncontrolling interests	(219)	(237)	(642)	(687)
Net income	1,219	579	3,170	1,723
Income tax expense	(360)	(133)	(881)	(396)
Loss from early extinguishment of debt	(5)	—	(5)	—
Other non-operating income, net	37	29	121	80
Interest expense	(203)	(206)	(612)	(616)
Operating income	1,750	889	4,547	2,655
Revenue from contract termination	646	—	1,472	—
Depreciation and amortization	(217)	(218)	(661)	(632)
Impairment and restructuring charges, and acquisition-related costs	(37)	(23)	(92)	(66)
Litigation and investigation benefit (costs)	(6)	11	(36)	(34)
Net gains on sales, consolidation and deconsolidation of facilities	9	20	43	4
Adjusted EBITDA	**$ 1,355**	**$ 1,099**	**$ 3,821**	**$ 3,383**
Net operating revenues	**$ 5,631**	**$ 5,289**	**$ 16,627**	**$ 15,783**
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues	**17.8 %**	**6.5 %**	**15.2 %**	**6.6 %**
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)	**24.1 %**	**20.8 %**	**23.0 %**	**21.4 %**

Supplemental Non-GAAP Disclosures

Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow

(Unaudited)

(Dollars in millions)	2026 Q3	2026 YTD
Net cash provided by operating activities	**$ 1,281**	**$ 3,507**
Purchases of property and equipment	(198)	(546)
Free cash flow	**$ 1,083**	**$ 2,961**
Net cash used in investing activities	**$ (298)**	**$ (818)**
Net cash used in financing activities	**$ (479)**	**$ (2,898)**
Net cash provided by operating activities	**$ 1,281**	**$ 3,507**
Less:		
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(19)	(103)
Cash received for contract termination	—	540
Adjusted net cash provided by operating activities	**1,300**	**3,070**
Purchases of property and equipment	(198)	(546)
Adjusted free cash flow	**$ 1,102**	**$ 2,524**

(Dollars in millions)	2025 Q3	2025 YTD
Net cash provided by operating activities	**$ 1,058**	**$ 2,809**
Purchases of property and equipment	(280)	(646)
Free cash flow	**$ 778**	**$ 2,163**
Net cash used in investing activities	**$ (385)**	**$ (886)**
Net cash used in financing activities	**$ (323)**	**$ (1,967)**
Net cash provided by operating activities	**$ 1,058**	**$ 2,809**
Less:		
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(3)	(84)
Adjusted net cash provided by operating activities	**1,061**	**2,893**
Purchases of property and equipment	(280)	(646)
Adjusted free cash flow	**$ 781**	**$ 2,247**

Supplemental Non-GAAP Disclosures

Table #4 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available to Common Shareholders

(Unaudited)

(Dollars in millions, except per share amounts)	FY 2026 Low	FY 2026 High
Net income available to Tenet Healthcare Corporation common shareholders	**$ 2,973**	**$ 3,078**
Less:		
Revenue from contract termination	1,650	1,650
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)	(180)	(150)
Net gains on sales, consolidation and deconsolidation of facilities(2)	43	43
Loss from early extinguishment of debt(2)	(5)	(5)
Tax and noncontrolling interests impact of above items	(365)	(370)
Adjusted net income available to common shareholders	**$ 1,830**	**$ 1,910**
Diluted earnings per share	**$ 35.82**	**$ 37.08**
Less:		
Revenue from contract termination	19.88	19.88
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements	(2.17)	(1.81)
Net gains on sales, consolidation and deconsolidation of facilities	0.52	0.52
Loss from early extinguishment of debt	(0.06)	(0.06)
Tax and noncontrolling interests impact of above items	(4.40)	(4.46)
Adjusted diluted earnings per share	**$ 22.05**	**$ 23.01**
Weighted average dilutive shares outstanding (in thousands)	**83,000**	**83,000**

(1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

(2) The Company does not generally forecast net gains (losses) on sales, consolidation and deconsolidation of facilities or gains (losses) from early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2026.

Supplemental Non-GAAP Disclosures

Table #5 – Reconciliations of Outlook Net Income Available to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA

(Unaudited)

(Dollars in millions)	FY 2026 Low	FY 2026 High
Net income available to Tenet Healthcare Corporation common shareholders	**$ 2,973**	**$ 3,078**
Less:		
Net income available to noncontrolling interests	(910)	(960)
Income tax expense	(1,135)	(1,170)
Interest expense	(825)	(815)
Loss from early extinguishment of debt(2)	(5)	(5)
Other non-operating income, net	150	200
Net gains on sales, consolidation and deconsolidation of facilities(2)	43	43
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)	(180)	(150)
Depreciation and amortization	(865)	(915)
Revenue from contract termination	1,650	1,650
Adjusted EBITDA	**$ 5,050**	**$ 5,200**
Net income available to Tenet Healthcare Corporation common shareholders	**$ 2,973**	**$ 3,078**
Net operating revenues	**$ 22,050**	**$ 22,450**
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues	**13.5 %**	**13.7 %**
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)	**22.9 %**	**23.2 %**

(1) The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

(2) The Company does not generally forecast net gains (losses) on sales, consolidation and deconsolidation of facilities or gains (losses) from early extinguishment of debt because the Company does not believe that it can forecast these items with sufficient accuracy since it is indeterminable at the time the Company provides its financial Outlook. The figures shown relate to transactions that have already occurred in 2026.

Supplemental Non-GAAP Disclosures

Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow

(Unaudited)

(Dollars in millions)	FY 2026 Low	FY 2026 High
Net cash provided by operating activities	**$ 3,885**	**$ 4,315**
Purchases of property and equipment	(700)	(800)
Free cash flow	**$ 3,185**	**$ 3,515**
Net cash provided by operating activities	**$ 3,885**	**$ 4,315**
Less:		
Payments for restructuring charges, acquisition-related costs and litigation costs and settlements[1]	(180)	(150)
Cash received for contract termination	540	540
Adjusted net cash provided by operating activities	**3,525**	**3,925**
Purchases of property and equipment	(700)	(800)
Adjusted free cash flow[2]	**$ 2,825**	**$ 3,125**

(1) The figures shown represent the Company's estimate for restructuring payments plus the actual year-to-date payments for restructuring charges, acquisition-related costs, and litigation costs or settlements. The Company does not generally forecast payments for acquisition-related costs, and litigation costs and settlements because it does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

(2) The Company's definition of Adjusted Free Cash Flow does not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows From Financing Activities on the Company's Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, and (ii) distributions paid to noncontrolling interests.


Tenet
Health